Once-a-day stimulant is safe for ADHD, can be used after 1 year

Published Date: 13 Mar 2023

New research shows that once-daily speech-stimulating medications for the treatment of ADHD in people age 6 and older are safe and effective after one year of pain treatment.

Read Full News

Latest News

NeuroVoices: Katrina Bawden, MSN, MSCN, FNP-C, on Emerging Therapies and Women’s Health Priorities in Multiple Sclerosis Katrina Bawden, MSN, MSCN, FNP-C

A nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.

FDA Accepts New Drug Application for Orexin Agonist Oveporexton in Narcolepsy Type 1, Grants Priority Review Isabella Ciccone, MPH

The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.

NeurologyLive® Brain Games: February 8, 2026 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on diagnosing parasomnias!

Remelyinating Drug Bazedoxifene Fails to Meet End Points in Phase 2 Study of Multiple Sclerosis Louie Pasculli

Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.

ISC 2026 Stroke Updates: Extended Time Windows and Secondary Prevention Strategies Ava L. Liberman, MD, Isabella Ciccone, MPH

Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.

Interpreting the DAWN Trial: Where Anti-CD38 Therapy May Fit in NMOSD Care Marco Meglio

Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

Todays Updates

Lilly's Zepbound and Taltz Improve Psoriasis Symptoms, Drive Weight Loss in Study

Eli Lilly said on Wednesday its weight-loss drug, Zepbound, used with psoriasis treatment Taltz, showed ⁠better results in patients with the skin disease and obesity in a...

Bimekizumab Eases Plaque Psoriasis Symptoms Up to 3 Years

Patients with moderate‑to‑severe plaque psoriasis achieve greater relief from itching, skin pain, and scaling with bimekizumab vs secukinumab up to 3 years.

Amivantamab Tied to Diverse Dermatologic Events in NSCLC

Treatment with amivantamab is associated with a broad spectrum of dermatologic adverse events that can be severe in patients with non-small cell lung cancer, a real-world study shows.

Measles Cases in South Carolina Rise by 12 to 962, State Health Department Says

South Carolina reported a surge to 962 measles cases on Tuesday, state health data showed, including ⁠12 additional infections since Friday, as officials warned the widening...

Urgent TRUE METRIX Glucose Meter Alert Updates Error Message

As currently written, the instructions could potentially lead to delayed treatment of high glucose levels.

Rural vs Urban: The Neonatal Care Divide in US Hospitals

An expansion of higher-level neonatal care has been observed in urban hospitals in the US over the years, whereas rural hospitals have faced a decline in such care capacity, per a recent study.

Todays Updates

Lilly's Zepbound and Taltz Improve Psoriasis Symptoms, Drive Weight Loss in Study

Eli Lilly said on Wednesday its weight-loss drug, Zepbound, used with psoriasis treatment Taltz, showed ⁠better results in patients with the skin disease and obesity in a...

Bimekizumab Eases Plaque Psoriasis Symptoms Up to 3 Years

Patients with moderate‑to‑severe plaque psoriasis achieve greater relief from itching, skin pain, and scaling with bimekizumab vs secukinumab up to 3 years.

Amivantamab Tied to Diverse Dermatologic Events in NSCLC

Treatment with amivantamab is associated with a broad spectrum of dermatologic adverse events that can be severe in patients with non-small cell lung cancer, a real-world study shows.

Measles Cases in South Carolina Rise by 12 to 962, State Health Department Says

South Carolina reported a surge to 962 measles cases on Tuesday, state health data showed, including ⁠12 additional infections since Friday, as officials warned the widening...

Urgent TRUE METRIX Glucose Meter Alert Updates Error Message

As currently written, the instructions could potentially lead to delayed treatment of high glucose levels.

Rural vs Urban: The Neonatal Care Divide in US Hospitals

An expansion of higher-level neonatal care has been observed in urban hospitals in the US over the years, whereas rural hospitals have faced a decline in such care capacity, per a recent study.

Latest News

A nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.

The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on diagnosing parasomnias!

Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.

Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.

Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

News All Time

Comparative Study Reveals Psychiatric Comorbidities Common in MOGAD, MS, and NMOSD, With Distinct Timing Patterns Isabella Ciccone, MPH

A new comparison study of patients with autoimmune diseases reported high rates of anxiety and depression, with notable differences in when psychiatric symptoms emerged relative to disease onset.

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib Isabella Ciccone, MPH

A phase 3b study presented at ACTRIMS 2026 is evaluating whether switching to remibrutinib offers efficacy and safety comparable to continued ocrelizumab treatment in relapsing multiple sclerosis.

Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers Marco Meglio

Findings from a phase 1 study indicated that Lucid-21-302 was generally well tolerated and exhibited dose-proportional exposure, warranting additional study in a phase 2 trial for multiple sclerosis.

CD40L Inhibitor Frexalimab Enters Phase 3 FREXITE Trial of Non-Relapsing Secondary Progressive Multiple Sclerosis Marco Meglio

New phase 3 FREXCITE trial tests frexalimab CD40L inhibitor in nrSPMS, comparing on-body subcutaneous vs IV dosing

Subgroup Signals Emerge for rFVIIa in Acute Intracerebral Hemorrhage in Phase 3 FASTEST Trial Marco Meglio

FASTEST finds rFVIIa curbs ICH bleeding fast but adds clot risk; ultra-early and spot-sign patients show promise as Part 2 continues.

Late-Breaking CHOICE 2 Data Indicate Alteplase Displayed Improved Stroke Recovery Louie Pasculli

Adding intra-arterial alteplase after successful endovascular thrombectomy significantly improved 90-day functional outcomes in patients with large-vessel acute ischemic stroke, according to late-breaking data from the phase 3 CHOICE2 trial.

Cladribine Maintains Efficacy, Safety Profile in Older Patients With Multiple Sclerosis Marco Meglio

Real-world phase 4 data show cladribine keeps relapse rates low and safety steady in relapsing MS patients, including those 65+.

Real-World Data Analysis Highlight Clinical Profiles and Inebilizumab Use Patterns in NMOSD Isabella Ciccone, MPH

A cohort analysis, presented at ACTRIMS 2026, provided insight into the clinical characteristics, disease burden, and treatment sequencing of patients with neuromyelitis optica spectrum disorder treated with inebilizumab.

Cladribine Tablets Show Ability to Improve or Stabilize Cognitive Function in Patients With Relapsing Multiple Sclerosis Noah Stansfield

The analysis included 280 patients from CLARIFY-MS extension and 219 patients from MAGNIFY-MS extension, a total of 499 patients with at least 4 years of follow-up.

CREST-2 Substudy Shows No Cognitive Benefit of Carotid Revascularization in Asymptomatic Carotid Stenosis Isabella Ciccone, MPH

Late-breaking data from a substudy of the CREST-2 trial revealed that carotid revascularization did not show greater improvements in cognitive function compared with intensive medical management.

Biomarker Data Across Studies Support Disease-Targeted Effects of Valiltramiprosate Marco Meglio

Newly reported data showed that oral valiltramiprosate lowers p-tau217 and links to cognitive and brain-volume benefits in early Alzheimer disease.

NeuroVoices: Benjamin Tolchin, MD, FAAN, on First-Ever AAN Guidelines for Functional Seizures Marco Meglio

The director of the Center for Clinical Ethics at Yale New Haven Health discussed the rationale behind the newly published AAN guidelines on functional seizures, outlining diagnostic priorities, evidence-based treatment recommendations, and key gaps.

National Women Physicians Day: Learning, Leading, and Lifting Others in Neurology Marco Meglio, Merit Cudkowicz, MD, MSc

ALS expert Merit Cudkowicz, MD, MSc, provided thoughts for National Women Physicians Day, reflecting on resilience in ALS research, the power of mentorship, and how leadership and advocacy can shape a meaningful career in neurology.

National Women Physicians Day: Perspectives From Riley Bove, MD Louie Pasculli, Riley Bove, MD

Riley Bove, MD, MS, associate professor of neurology at the University of California San Francisco, shares her personal view on National Women’s Physician’s and why it’s important for clinicians and patients in the field.

Women Physicians Day 2026: Prioritizing Whole-Person Care for Women With Movement Disorders Isabella Ciccone, MPH, Jill Farmer, DO, MPH, FCPP, DipABLM, Kelly Papesh, DNP, APRN, FNP-C, CMRD, Madhureeta Achari, MD, Joanna Dearlove, MD

As part of National Women Physicians Day, a group of women clinicians discussed various topics in the care for women with movement disorders.

National Women Physicians Day: Insights From Aleksandra Pikula, MD, DipABPN, DipABLM, FELMO Aleksandra Pikula, MD, DipABPN, DipABLM, FELMO, Louie Pasculli

Aleksandra Pikula, MD, DipABPN, DipABLM, FELMO, director of the JS Sonshine Center, shares her personal view on National Women Physician’s and why it’s important for clinicians and patients in the field.

Recommended News For You

Base-edited T-cell therapy offers additional hope for treating resistant leukemia.

BMI is linked to heart damage from chemotherapy in breast cancer patients.

Who Bears the Cost of "Forever Chemical" Cleanup?

The acceptance of innovative hormonal therapy for advanced prostate cancer is racialized.

Liver cancer survival rates reflect income disparities

To automate the biopharmaceutical facilities of Reliance Life Sciences, ABB India has won the contract.

AI Unlocks Benefits of Prostate Cancer Treatment.

Recommended Articles For You

Asymptomatic Thrombocytopenia: Unraveling the Enigma of Low Platelet Counts Without Symptoms 

Preventing Heparin Induced Thrombocytopenia: Tips for Successful Anticoagulation Therapy  

Managing Hematoma: A Guide to Prevention and Treatment 

Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA Approves New Bladder Cancer First-Line Standard of Care.

2.

UK government can save lives and smash inequalities by changing prostate cancer guidelines, say experts

3.

Surgeons are at higher risk of cancer, study suggests

4.

An Eye Surgeon's Unexpected Discovery of the "Before and After".

5.

Anticoagulation for 12 months has been found to improve outcomes in cancer patients with minor blood clots.

1.

AI-Driven Chemotherapy: Transforming Cancer Care with Precision and Efficiency

2.

Obesity is a major risk factor for cancer

3.

Antibody-Drug Conjugates in Oncology: Breakthroughs, Clinical Updates, and Pipeline Innovation

4.

Revolutionizing Cancer Treatment: How Adoptive Cell Therapy is Overcoming Tumor Immune Evasion

5.

Tazemetostat: A Promising New Treatment for Cancer

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation

2.

Current Scenario of Cancer- Palliative Care to Close the Care Gap

3.

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

4.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV

5.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot